752 results on '"Nout, Remi"'
Search Results
102. Supplementary figure 3 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
103. Supplementary table 1 from POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
104. Can we improve survival with less overall morbidity for patients with intermediate-risk cervical cancer without the use of external beam radiotherapy?
105. HYpofractionated, Dose-redistributed RAdiotherapy with protons and photons to combat radiation-induced immunosuppression in head and neck squamous cell carcinoma: study protocol of the phase-I HYDRA trial
106. Erratum: Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium
107. Overall severe morbidity after chemo-radiotherapy and MRI guided adaptive brachytherapy in locally advanced cervical cancer: results from the EMBRACE–I study
108. Closing the gap for cervical cancer research in Vietnam: current perspectives and future opportunities: a report from the 5th Gynecologic Cancer InterGroup (GCIG) Cervical Cancer Research Network (CCRN) Education Symposium
109. Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial
110. Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study
111. Prognostic significance of L1CAM expression and its association with mutant p53 expression in high-risk endometrial cancer
112. Long-Term Impact of Endometrial Cancer Diagnosis and Treatment on Health-Related Quality of Life and Cancer Survivorship: Results From the Randomized PORTEC-2 Trial
113. Selecting Adjuvant Treatment for Endometrial Carcinoma Using Molecular Risk Factors
114. MRI-driven design of customised 3D printed gynaecological brachytherapy applicators with curved needle channels
115. Molecular Classification Predicts Response to Radiotherapy in the Randomized PORTEC-1 and PORTEC-2 Trials for Early-Stage Endometrioid Endometrial Cancer.
116. ESTRO/ESGO/SIOPe Guidelines for the management of patients with vaginal cancer.
117. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative
118. Qualitative Accounts of Patients' Determinants of Vaginal Dilator Use after Pelvic Radiotherapy
119. Nomograms for Prediction of Outcome With or Without Adjuvant Radiation Therapy for Patients With Endometrial Cancer: A Pooled Analysis of PORTEC-1 and PORTEC-2 Trials
120. Health related quality of life and patient reported symptoms before and during definitive radio(chemo)therapy using image-guided adaptive brachytherapy for locally advanced cervical cancer and early recovery — A mono-institutional prospective study
121. Post radiation mucosal ulcer risk after a hypofractionated stereotactic boost and conventional fractionated radiotherapy for oropharyngeal carcinoma
122. Brachytherapy training survey among radiation oncology residents in Europe
123. EP116/#725 Low-grade p53abn endometrial carcinomas exist and are associated with a high risk of recurrence, even in low-stage disease
124. Image-Guided Brachytherapy for Rectal Cancer: Reviewing the Past Two Decades of Clinical Investigation
125. 2022-RA-925-ESGO Development of adjuvant treatment decision support tool for endometrial cancer patients by pooled analysis of data from 2000 women included in the PORTEC-1–3 trials and a prospective cohort study
126. 2022-RA-743-ESGO Improving risk stratification for cervical cancer in patients treated with concurrent chemoradiation and MRI-image guided adaptive brachytherapy in EMBRACE study: results from an international collaborative translational research study (BIOEMBRACE-I)
127. 2022-RA-934-ESGO Vaginal changes, sexual functioning and distress of women with locally advanced cervical cancer treated in the EMBRACE vaginal morbidity sub-study
128. 2022-RA-568-ESGO Prognostic Relevance of FIGO grading is Limited to NSMP Endometrial Cancers
129. 2022-RA-825-ESGO The impact of age on prognosis in women with endometrial cancer: a pooled analysis of the PORTEC-1, -2 and -3 randomised trials
130. 2022-RA-450-ESGO Benefit of adjuvant radiotherapy depends on molecular class of early-stage endometrial cancer
131. 2022-RA-809-ESGO Underlying causes and prognosis of mismatch repair deficiency in endometrial cancer other thanMLH1promoter hypermethylation
132. 2022-RA-648-ESGO Interpretable deep learning provides clues for prognostic refinement of the molecular endometrial cancer classification
133. Patient-derived breast model repository, a tool for hyperthermia treatment planning and applicator design
134. Posttraumatic Stress Disorder After High-Dose-Rate Brachytherapy for Cervical Cancer With 2 Fractions in 1 Application Under Spinal/Epidural Anesthesia: Incidence and Risk Factors
135. Manifestation Pattern of Early-Late Vaginal Morbidity After Definitive Radiation (Chemo)Therapy and Image-Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: An Analysis From the EMBRACE Study
136. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma
137. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer
138. Multi-center analysis of machine-learning predicted dose parameters in brachytherapy for cervical cancer
139. Multicentre treatment planning study of MRI-guided brachytherapy for cervical cancer: Comparison between tandem-ovoid applicator users
140. Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer:An EMBRACE-I sub-study
141. Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists
142. Role of Brachytherapy in the Postoperative Management of Endometrial Cancer: Decision-Making Analysis among Experienced European Radiation Oncologists
143. Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry.
144. Post radiation mucosal ulcer risk after a hypofractionated stereotactic boost and conventional fractionated radiotherapy for oropharyngeal carcinoma.
145. High-grade soft tissue sarcomas of the extremities: surgical margins influence only local recurrence not overall survival
146. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K–AKT, Wnt/β-catenin and P53 pathway activation
147. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial Cancer (PORTEC-2) trial and comparison with norm data
148. Dose-effect relationship between vaginal dose points and vaginal stenosis in cervical cancer: An EMBRACE-I sub-study
149. Vaginal brachytherapy management of stage I and II endometrial cancer
150. Prognostic relevance of the molecular classification in high-grade endometrial cancer for patients staged by lymphadenectomy and without adjuvant treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.